Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Link to that data on A/S ?
This scam's been exposed for years, but "hopium" is a powerful drug.
What the hell happened to this ticker did they have a reverse split?
docsetc Can you reach out and ask if the Doctor can provide proof ITV-1 failed and when, with what has been reported in PR's and the July 1st PR would be proof that someone is lying about ITV-1 and if Harry is that is what the SEC and lawyers would love to see. I am about to selloff the remaining 500k of shares to put into R S P I . I dont see this going anywhere under Harry and an expanding A/S. Agreed a split is the next step for them. They stated in this past PR the trials in EU will underway when SAGA is listed, we were told a year ago that that was underway . Hum. GLTA
NEWS
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Update on Sagaliam Acquisition Corp.
ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, "Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells," applying Immunotherapy Treatment to the global fight against cancer. ENZC continues to explore therapeutic applications of the patent, and is preparing to commence Federal Drug Administration ("FDA") in-vitro studies. ENZC has developed a Statement of Work with a major university in Texas to further this effort.
In the interim, the Company will pursue various regulatory paths under "Right to Try Laws" for application to terminally ill stage four cancer patients. This could be achieved by approval of an individual IND to help prolong lives. Immune treatment, such as ITP-immune therapeutic protein, does not substitute for existing chemo therapy treatments.
Additionally, Dr. Lachezar Ivanov, Director of ENZC and member of the Bulgarian Senate, is negotiating the acquisition of a pharmaceutical manufacturing facility in Bulgaria which meets the Good Manufacturing Process ("GMP") standard required by the European Medicine Association ("EMA"). The manufacturing facility will be an integral part of the ENZC portfolio of products for the nutraceutical market as well as the manufacturing and distribution of its other licensed immunotherapy treatments.
Sagaliam Acquisition Corp. ("SAGA") has provided the Company with an update on multiple efforts including its application with OTC Markets. Currently, SAGA has secured funding for completion of the necessary audits required for the next steps toward completion of its application for membership on the OTC board and has engaged a PCAOB auditor.
Operationally, SAGA has filed two new patent applications, one for its Multiple Sclerosis immunotherapy treatment, for which a provisional application was previously filed, and the other for the Peptide Complex modulation of the immune system. A worldwide license will be awarded by the patent owner for both treatments to SAGA. Progress is being made to move forward with clinical trials in Europe to assess the effects of ITV-1 on diabetic patients. Additionally, progress continues to be made on the permitting of ITV-1 for treatment of HIV/Aids with the EMA.
SAGA and ENZC are coordinating the dividend approval process of the shares issued in association with the sale by ENZC of Virogentics, Inc. to SAGA in September of last year. The make-whole provision will apply to all shares distributed to ENZC shareholders.
Harry Zhabilov, Chief Science Officer of ENZC and SAGA, stated, "Enzolytics' licensing of the Cancer immunotherapy treatment is an expansion of its cutting edge portfolio of technology IP and products. The continued growth of the product base of the Company and Saga will give us the opportunity to utilize the skills, experience and expertise of our management team and partners."
Steve Sharabura, the CEO of Enzolytics commented, "In addition to the exciting progress on intellectual property, we will continue to build a robust IP portfolio going forward. We are also enthusiastic about moving forward on our ETC Marketing initiative, with an initial focus on consumer sales of nutraceutical products. With the current explosion of online communities, we appreciate the value of digital marketing and the power of social media augmented by AI. As we expand our consumer engagement through ETC Marketing, we will also use these tools to increase engagement with our investors and expand awareness and education related to our well-being therapies."
Barry Kostiner, the CEO of Sagaliam commented, "We are looking forward to regaining compliance and getting SAGA listed on OTC. Historically, Enzolytics' valuation has exceeded $500M, reflecting the value of the ITV-1 intellectual property embedded in Virogentics. Once the SAGA OTC listing is in place, we will be able to issue the dividend of SAGA shares to Enzolytics, and complete the funding needed to move forward on clinical trials and bring ITV-1 to market. Our technology has been well established, and we have only a few regulatory steps needed to bring value to SAGA and ENZC shareholders and make significant contributions to global health. The application to HIV in Europe and Africa will be well on its way within 6 months of completing the SAGA OTC listing, and work on applications to diabetes and cancer would commence within another 6 months.
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to a sales, marketing and distribution entity focusing on medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
SOURCE: Enzolytics, Inc.
SeniorApollo, Based on the recent A/S increase, I will not be surprised to see the announcement of Reverse Split in the very near future.
Wow, crazy. I almost thought I was seeing things when I read this post and had to double check. Yep, sure enough! That is insane.
https://www.otcmarkets.com/stock/ENZC/security
Well, it's happening.
Authorized shares just updated from 3.9 billion to 5.5 billion.
We are officially fucked with zero help insight.
CCC can't even be bothered to put out a statement that clarifies any bit of this mess? I guess we bet on the integrity of the wrong team.
.."So Chandra knew itv1 failed, he knew saga was a scam. But proceeded with "we won" and just let everyone pump along for another year. How convenient."
(1) Why did Chandra lie about itv1 for Harry?
(2) is it because Chandra also needed ENZC PPS to be there so he could cash out more monies from the ENZC ATM machine as well ?
(3) or CCC and Harry are all in this together with all agreed division, such as...Harry got to keep ENZC company and pushing for the emptied SAGA so ENZC shareholders would stay and not leave so he could cash out his EZC ATM whenver he wanted; Charles went his seperate way and got to keep clone 3/7 which was further developed and refined while Charles was at ENZC; and chandra went his seperate way and got to keep his AI which was developed and refined while Chandra was employed at ENZC?
(4) or some other crooked reasons?
.....Time will tell; but ENZC shareholders have lost so much monies and time already. I believe they are all crooked in one way or another when messing around with ENZC shareholders' monies
It was not a post, it was direct communication from CCC. They said the Clone3/7 passed toxicology tests, ITV-1 did not.
I've got nothing but Chandra's word on this, but he was sounding pretty serious about it. Measure that as you will.
You will notice on the PR's about the alleged past toxicology testing, there was no data published about it.
GLTa
So Chandra knew itv1 failed, he knew saga was a scam. But proceeded with "we won" and just let everyone pump along for another year. How convenient.
Misleading is definitely an understatement. It's a real tangled web they've been weaving. I wouldn't be surprised if toxicity studies never even took place.
Yes here is a PR they put out in Feb 2023. So misleading would be an under statement .
https://finance.yahoo.com/news/enzolytics-announces-preliminary-results-glp-110000986.html
Copilot
Sent by Copilot:
Enzolytics ITV-1 is a patented immunotherapy cancer treatment developed by Enzolytics, Inc. It’s also known as Immune Therapeutic Vaccine-1 (ITV-1). Here are some key points about it:
Composition: ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which is the active drug substance. IPF is a purified extract of porcine pepsin.
Effectiveness: Studies have shown that ITV-1 is effective in treating HIV/AIDS by modulating the immune system12. It has broad efficacy with low toxicity.
Cancer Immunotherapy: Enzolytics has entered into a worldwide exclusive licensing agreement for US Patent #8067531-B2, which applies immunotherapy treatment to the global fight against cancer. The company is exploring therapeutic applications of this patent and preparing for FDA in-vitro studies. ITV-1 does not substitute for existing chemotherapy treatments3.
Clinical Trials: Progress is being made to move forward with clinical trials in Europe to assess the effects of ITV-1 on diabetic patients. Additionally, efforts continue for permitting ITV-1 for HIV/AIDS treatment with the European Medicine Association (EMA)34.
Manufacturing Facility: Enzolytics is negotiating the acquisition of a pharmaceutical manufacturing facility in Bulgaria that meets Good Manufacturing Process (GMP) standards. This facility will be part of their portfolio for nutraceutical products and licensed immunotherapy treatments3.
Once the SAGA OTC listing is in place, Enzolytics plans to issue dividends of SAGA shares and complete funding needed for clinical trials to bring ITV-1 to market3.
Learn more
1
nasdaq.com
2
biospace.com
3
finance.yahoo.com
4
nasdaq.com
https://finance.yahoo.com/news/enzolytics-announces-preliminary-results-glp-110000986.html
Still waiting for irrefutable scientific research/evidence any trials or tests took place. Lots of speculation and insider top secret convos with Chandra going on while the price decreases daily.
Until we see more than word of mouth, "bashers" can continue to say ENZC was a nothing but a well-engineered elaborate scam.
Dude...... give me a break
And he’s prob being honest. We were told in late 2022, leading into 2023 that they were doing those toxicology tests prior to the African trials starting and then it was nothing but silence after followed by multiple excuses of delays that then led to silence again. Then the whole mess with SAGA last fall up through CCC departing. So it makes sense in hindsight now how things played out that it could have failed those toxicology tests.
He can't link anything. He claims Chandra told him over the phone.
Everything I've read said it passed toxicity tests with flying colors. Link the failed test for African trials please.
This is the kind of announcement I'd like to see for ENZC one day. This is not for ENZC, but it could have been if they stuck to their original milestones schedule.
[url]
https://www.biospace.com/article/samsung-bio-nabs-1b-manufacturing-contract-with-undisclosed-us-pharma/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz-8HLsn97oMbtv9e9BguCseaO4lcKcHcOv7DB_n6Ave7u0jF-R3SxDUGx0C50Nzf--7xjLnaACzIsZhMRSXmCw05o7j9Sg&_hsmi=314119536&utm_content=314119536&utm_source=hs_email[/url][tag]insert-text-here[/tag]
They're could be trials for ITV-1 in Europe, but ITV-1 failed toxicology tests prior to the announced African volunteer trials. So, ITV-1, despite their claims, is mothballed for now. The last PR claiming a cancer treatment contract is pure bunk. Harry and Sharabura have nothing to sell. Maybe Dr. Tong can arrange for Sharabura to sell used Lunar Rover parts next.
Clone3/7 volunteer trials can only happen once the CCC bunch executes whatever they are deciding to do, and they're not even professional enough to put up a PR alerting concerned shareholders of any possible timeframe on just such an announcement.
Loose legal in OTC:Pink land, and always frustrating.
I would personally seal the container that Sharabura and Zhabilov stow away in..... leaving some good ol' Texas Rattlers to keep them entertained in the dark as they journey goes on. LMAO...
My one concern is, Harry will try a legal maneuver to hold onto ENZC, as he reopens something else. It should not work, but voting control could avert any serious legal issues to hold things up.
GLTA
Jack Torrance, A lot of people (shareholders) are pissed/confused over this. I imagine the lawsuits are multiplying. I am watching to see if Charles Cotropia initiates anything.
So, PRs in the past have promised us shares in SAGA, a Nasdaq company at the time. Now they are trying to get listed on the OTC. Are we going to get shares of SAGA once it's listed? And in light of misleading shareholders over that deal, doesn't that open ENZC to a class action lawsuit? I mean, a lot of people stayed invested because of the SAGA deal, and lots even increased their positions because of all those false promises that have not come to fruition. I mean, I'm pretty upset. This whole company is run by god-knows-who and seems to have been set back by about 5 years. And here we are, years later, and we are no closer to clinical trials for Clone 3 or ITV-1. What a joke. Sorry, I'm f**king pissed.
docsetc, Thanks, for the affirmation. I really think that the Cotropia’s are holding all the cards. Imo, Charles has two choices… one, to “go legal” on the Zhabilov’s, or… two, let the Zhabilov’s implode due to lack of funds. You notice that I don’t include the other questionable characters, because I think they are already imploding.
I wouldn’t be surprised if Barry sort of just disappears. There are plenty of freighters going down that Houston ship channel right past Baytown to non-extradition countries.
YES, even publish internal lab testing or animal testing even, something tangible telling the world officially that Clone3/7 works!
That makes a world of difference.
Pretty decent opinion and thought process Wick. I think for legal purposes, that this is highly likely, and ENZC has to be owning the two subs 100% per the dissolved deal. But, unless CCC comes back in charge with the IP's, it's an empty 3-way shell.
IMHO, it's going to come down to the voting control shares number, which allegedly swings CCC's way after SAGA shares are returned. Harry could wind up signing off quickly, as all those millions of preferred shares are useless without the MABS IP's. Either he allows the CCC group to run things, or his future is flushed down with his own shares value.
He may be just enough of an imbecile to burn it down, yes, "If I can't run it, I'll make sure you can't either...!" That sort of drama. Let's hope Charles has the right hammer for hitting the right nail on the head at the right time. This is what Chandra was alleging in his last few Twitter posts. I have 'some' faith in them, but not much at this point.
Or its just 3-way scamming until our PPS ends.
GLTA
Yes they have been beating the SP up the past few weeks , just like they did here before it ran. Its all a gamble but they show better results backing it up in trials than we were lead to believe was happening here years back. GLTA
Thanks Wick what a fiasco this has turned out to be. Hoping for the best.
PB, The rift between the two families has been going on since before the two subsidiaries were formed. It was not a solution as the Zhabilov’s wanted to sell for the sake of money. The Cotropia’s want to perfect their cures for society’s benefit.
Harry Zhabilov saw what he thought would be an easy way to collect millions, even though it was a questionable transaction done with questionable persons. Harry’s one problem was that the deal couldn’t be completed without the Cotropia’s IP.
Harry and the SAGA people tried to pull a fast one and issue shares to the Cotropia’s in violation of NASDAQ rules. As a result, SAGA was delisted from NASDAQ, which put the whole deal in the dumpster.
Now, the Zhabilovs are taking the position that deal has been completed, even in light of and against the NASDAQ ruling. The Cotropia’s are taking the position that the deal was canceled and never should have been attempted in the first place.
So, as shareholders, we can just watch and see if, and how, this all works out.
My take is, it will eventually revert back to the two subsidiaries being as it was prior to the failed SAGA fiasco. That will take some time, and I expect Harry Zhabilov to muck things up enough until he gets paid to go away.
All just my humble opinion…
This other ticket looks too be tanking too?
It's almost incredible, I bet you can't look at today's graph and tell when I made a buy, instantly down 40% afterwards.
Wick what is your take on what is going on with all this bullshit? Thanks
Whoa that symbol mentioned has a lot of history and SEC Deliquent right now. Similar to the LEAI of Barry K prior to SAGA , Beware. $ENZC #ENZC Clarifying SAGA situation. https://t.co/Nsp38YJizt pic.twitter.com/hohVxUT3kL
--
In any Case *speaking of cases, LOL.
$ENZC Well the Fraudlent Four of Harry, Barry , Kelli A and Steve S keep going through the revolving door of Lawsuits against them. Kelli A just was in and pleaded the Fifth, over 35 times on another case. One day soon it will all catch up with them. Barry K is not long for this world. Thanks KOP for the consistent and verified updates!
latest on Barry.
Although "$ENZC #ENZC Clarifying SAGA situation." is posted at the top of that tweet, the documents shown are for the GLD Principal Strategies, LLC v Barry Kostiner case. That case is about a $35,000 loan that Barry received and has not repaid. From what I see the case has already been decided against Barry, and the reason they are still filing documents is because he is failing to respond. If he received the loan via SAGA, shouldn't SAGA be listed as the Respondent? I see no mention of ENZC associated with this case. I am not taking a deep dive into this case because to me, aside from showing Barry's character and his disdain for the legal system, this has nothing to do with GLD v SAGA.
I have been building over there 14M , would love to see .10 one more time here but sure that is a long shot at this point . Once passed on I will checkout what u r looking at Thank you
Yeah, thanks to you, I've got them in my watchlist now. May take a jump at them. Also have some energy companies that if Trump wins, they will rocket. In fact one already did, but came down since Biden refused permits. (And then this last April, Congress awarded them a tax-free factory site.)
I've got about a half-dozen new targets, will sell all off if this takes a sudden spike to about .11c pps, under current management. If CCC does get back in there, then I may hold. I may even buy another 100-200K shares in the trips, just to make a pumper-spike a decent sell-off value.
Thanks for the tip, I like what you showed me. I'll pass a couple back to you soon.
GLTY
I am not expecting anything , I was one of the ones saying that the SAGA deal wasn't legal and it would come out.
Is going to be hard to be expecting anything from SAGA..KOP just posted a court filing update, and is not looking good for them:
$ENZC #ENZC Clarifying SAGA situation. https://t.co/Nsp38YJizt pic.twitter.com/hohVxUT3kL
— King of Prussia (@ImKingofPrussia) July 2, 2024
Yeap basically same wording they put out awhile back. Total BS . Not expecting anything from SAGA since they have no shares to give. I reduced my holding down to 500k . Moved onto R S P I a better Biotech IMO atleasted funded by DOD and are in trials . GLTA
Their announcement they put out today, did in fact claim they are moving forward with the dividend. This means, if they pull it off, our shares will be useless and without value, as they dilute down the SAGA shares we'd be getting. They are betting on the fact they could use of every share dollar of ENZC soon, and not owe current common shareholders anything as they move over to SAGA. So, you may get around $1K per every 500K shares, or less, and next to nothing in SAGA shares, if they are ever worth anything.
They are betting on running away while standing in plain view, since they don't think OTC shareholders will drum up a class-action lawsuit.
I did file my complaint with the SEC. Barry and Harry need to go be butt-buddies in a Federal Pen.
GLTA
Well if they claim SAGALIAM is alive and well where are the dividend we are owed, All emails have gone unanswered dealing with that from them. GLTA
Well, you're still wrong. There are notable cases where OTC offenders went to jail for what they did. The SEC would rather not even hear of an OTC case, but if they get solid proof dumped on them of shareholder defrauding, they can and eventually do take action.
I'd be satisfied with just the official notice to be landed on Harry's desk, warning of a possible SEC investigation. That usually sends the OTC frauds running at the very least.
It's rare, but it can happen. This ENZC fiasco gets nastier the longer Zhabilov has lone control, and more fantasy-land. I give them credit for quite the pump with this latest nonsense, and notice the Forward Statements just tripled in size from old ENZC PR's.
So pathetic.
GLTA
Yeah, best evidence I can see, is that they need money badly. I see nothing official that even indicates SAGALIAM even has life left to it. I'm kinda' surprised Kostiner came out to put a quote out, if he actually did. No assets listed, no mention of Kostiner's and Zhabilov's current legal case load in court, and now Sharabura just flipped back from used medical equipment to new biopharma pursuits, "They" are going to acquire a pharmaceutical testing company?
With what, a newly issued 3 billion more common shares?
No assets, no word of where THIS funding came from, and Chandra swears that ITV-1 failed toxicology tests, but Zhabilov has a cancer treatment program even interested in it ??
Maybe they'll fool the day traders into running this back up to .10c pps. Not sure. Baytown's not all that far away from me, maybe I go mug Sharabura and strap him to a lie detector, see if anything other than online pumps are going on. Really, who would even sign this group to sell lemonade on their streetfront ??
No one cares about securities fraud in the OTC. Read that a few times.
This is securities fraud - when ENZC issues a press release and they knowingly include false and misleading information.
"Operationally, SAGA has filed two new patent applications, one for its Multiple Sclerosis immunotherapy treatment, for which a provisional application was previously filed, and the other for the Peptide Complex modulation of the immune system. A worldwide license will be awarded by the patent owner for both treatments to SAGA. Progress is being made to move forward with clinical trials in Europe to assess the effects of ITV-1 on diabetic patients. Additionally, progress continues to be made on the permitting of ITV-1 for treatment of HIV/Aids with the EMA.
SAGA and ENZC are coordinating the dividend approval process of the shares issued in association with the sale by ENZC of Virogentics, Inc. to SAGA in September of last year. The make-whole provision will apply to all shares distributed to ENZC shareholders."
The SAGA stock isn't traded on Nasdaq or the OTC. SAGA was delisted from Nasdaq for multiple reasons. ENZC is Dark and not a SEC reporting company. The SAGA shares have no value.
Plus, the press release contained: "Operationally, SAGA has filed two new patent applications, one for its Multiple Sclerosis immunotherapy treatment, for which a provisional application was previously filed"
So Barry Kostiner filed two new patent applications. LMAO!
The SAGA deal was never consummated - plus SAGA has other lawsuits to deal with - the deal has been dead since the day it was announced.
IG
More bad news a regurgitated press release that is meaningless.
"ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2,"
From the USPTO:
US8067531B2
United States
Inventor: Harry H. Zhabilov
2008-12-02: Application filed by Individual
2011-11-29: Application granted
2025-07-11: Anticipated expiration
Assignors
ZHABILOV, HARRY H.
ZHABILOV, DIANA
Execution date: Oct 31, 2009
Assignee: THE ZHABILOV TRUST
2210 ASHBOURNE DRIVESAN MARINO, CALIFORNIA 91108
The Patent Expires in a year.
And it is assigned the The Zhabilov Trust.
Just more pumping nonsense.
IG
Better strap on your s*it scuba diving gear b4 you explore the crew mentioned in this PHD PR. This report smells worse than Bidens’ diaper. Stevie Wonder could see it a mile away. LOL. NO need to investigate or DD for these ppl. imo.
Independent Valuation Report Pre Clinical Studies
Investments
___________________________________________________________________________________
Press Release July 20-2021
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc.
for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
https://www.creative-biolabs.com/
https://finance.yahoo.com/news/enzolytics-announces-signing-letter-intent-113000339.htm
________________________________________
Press release July 21-2021
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and
Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
https://www.lonza.com/
https://www.bloomberg.com/press-releases/2021-07-21/enzolytics-and-lonza-bioscience-combine-technologies-to-fast-track-development-and-production-of-anti-hiv-and-anti-sar
_________________________________________
July 22 INTERVIEW
with
James Hicks, Charles Cotropia and Gurav Chandra
http://www.youtube.com/watch?v=mdljO9VLgj0
______________________________________________________________
COLLEGE STATION, TX August 25, 2021
Important Excerpt from this news progress update.
>>>>>><<<<<<
"The monoclonal antibodies being produced by Enzolytics against the CoronaVirus target 19 conserved immutable sites on the virus, sites which the Company has now confirmed are conserved sites not only on the initial virus strains but also existing in the Delta and Lambda variants, as well as in the Alpha, Beta and Gamma variants."
Enzolytics Inc. and Samsung Biologics Announce
Development and Manufacturing Agreement for Anti-
HIV and Anti-SARS-CoV-2
Important Excerpt from this news progress update.
>>>>>><<<<<<
"Samsung Biologics (KRX: 207940. K.S.), a leading contract development and manufacturing organization and Enzolytics (ENZC), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, announced the signing of a strategic CDMO partnership agreement."___
2000 North Central Expressway
Plano, TX 75074
972-292-9414
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |